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Summary
PRINCIPLES: Current evidence indicates that chronic kid-
ney disease (CKD) can be detected by simple laboratory
tests. This study aimed to evaluate the cost-effectiveness
of microalbuminuria screening and subsequent treatment in
different populations.
METHODS: Cost-effectiveness of microalbuminuria
screening in a cohort of simulated subjects aged ≥50 years
was assessed using a validated microsimulation model. Mi-
croalbuminuria screening was simulated for 1-, 2-, 5- or
10-year intervals and for 3 groups: diabetes (DM), hyper-
tension but no diabetes (HTN), and no diabetes or hyper-
tension. Positive microalbuminuria screening was followed
by treatment with angiotensin-converting enzyme (ACE)
inhibitors or angiotensin II receptor blockers (ARBs). The
model outcomes evaluate costs from a health care system
perspective.
RESULTS: Screening of risk groups is cost-effective at
a 2-year interval for the DM group with an incremental
cost-effectiveness ratio (ICER) of 54,000 CHF/ Quality-
Adjusted-Life-Years (QALY) and at a 5-year interval for
the HTN group with an ICER of 33,000 CHF/QALY.
Screening of the remaining population is cost-effective at
a 10-year interval with an ICER of 34,000 CHF/QALY.
The ICER improves with longer screening intervals for
all groups. A probabilistic sensitivity analysis (PSA) con-
firmed 2-year, 5-year and 10-year intervals as the most
cost-effective for the DM group, the HTN group and the re-
maining population respectively.
CONCLUSIONS: Microalbuminuria screening can be con-
sidered cost-effective starting at the age of 50 years at bi-
annual intervals for subjects with diabetes, at 5-year inter-
vals for subjects with hypertension and at 10-year intervals
for the remaining population. Our results indicate that early
detection and treatment of CKD might lead to optimised
patient care, and offer guidance for future implementation
of CKD screening programmes.
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Introduction
Chronic kidney disease (CKD) is a major public health
problem with a worldwide prevalence of around 13% and
enormous associated costs. Aging populations and the rise
of diabetes, hypertension and obesity are expected to fur-
ther increase the prevalence of CKD in the near future [1,
2].
End-stage renal disease (ESRD) is associated with high
mortality and a significant cost burden. In Switzerland,
ESRD subjects on dialysis represent about 0.05% of the
population. Average yearly costs of 78,000 CHF per ESRD
patient correspond to 1.1% of the total health care ex-
penditure covered by social health insurance [3, 4]. Not
only ESRD but also less severe CKD stages 2–4 are associ-
ated with high health care costs due frequent medical treat-
ments [5, 6].
Currently there is no cure for CKD. However the rate of
disease progression and associated morbidity and mortal-
ity can be reduced. Several studies have demonstrated that
an early intervention, for example with angiotensin-con-
verting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARBs), can slow the progression of renal decline
and reduce the cardiovascular (CV) morbidity [1].
CKD is often unrecognised, but can be detected by simple
tests with acceptable reliability [7, 8]. Since CKD is “com-
mon, harmful and treatable” it seems to be a condition
predisposed for national screening programmes [7]. Public
awareness campaigns for screening programmes of high
risk groups such as people with diabetes, hypertension and
a history of CV disease have recently been recommended
for each country [2, 9, 10]. In addition to the high risk
groups, broader targeted screening for people of an older
age, with a family history of kidney disease or other car-
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diovascular risk factors has been suggested as well [9].
However before implementation, the cost-effectiveness of
these programmes should first be evaluated in the frame
of the country specific health care system and cost struc-
ture. Only a few health economic evaluations of such pro-
grammes have been performed to date. While a Dutch
study indicated that microalbuminuria screening of the
general adult population followed by treatment with ACE
inhibitors could be cost-effective, other studies recommen-
ded only the testing and subsequent treatment of selected
high risk populations such as people with diabetes or hy-
pertension [11–14].
The aim of this study was to estimate, for the first time, the
cost-effectiveness of microalbuminuria screening for CKD
in different patient populations in the frame of the Swiss
health care system. We adapted a recently developed CKD
microsimulation model and report the results for different
screening scenarios from a health care system perspective
[15].
Methods
We performed a cost-effectiveness analysis of microalbu-
minuria screening in Switzerland by adapting a microsimu-
lation model which was recently developed for the US [14,
15]. The adaptation to the Swiss context covered the fol-
lowing model parameters: 1) prevalence and incidence of
risk factors for CKD, 2) demography (racial composition,
all-cause mortality) and 3) cost of screening and treatment.
When an adaptation was not possible due to lack of Swiss
data, this is stated explicitly in the Tables 1 to 3 describing
the model parameters.
The current analysis was carried out from a Swiss health
care system perspective.
Model structure
The model has been described in detail previously [14, 15].
Briefly, the model simulates a cohort of persons from age
30 until age 90 or death. The model includes seven states:
Figure 1
Scheme of screening and treatment interventions.
ACE/ARB: Angiotensin-converting enzyme inhibitors or angiotensin
II receptor blockers; ACR: Urine albumin-creatinine ratio; GFR:
Glomerular filtration rate.
The same screening and treatment scheme does apply for patients
with macroalbuminuria. Such patients will also be detected in a
microalbuminuria screening.
Modified and reproduced from Hoerger TJ, Wittenborn JS, Segel
JE, Burrows NR, Imai K, Eggers P, et al.Am J Kidney Dis.
2010:55(3):463–73, with the permission of Elsevier.
no CKD, CKD stages 1–5, and death. The classification
of CKD stages is based on the Kidney Disease Outcomes
Quality Initiative (KDOQI) guidelines and is defined by
glomerular filtration rate (GFR) and the presence of kidney
damage/albuminuria. Disease parameters are derived from
the epidemiological literature, clinical trials, and a previous
cost-effectiveness study by Boulware et al. [13].
Progression through CKD stages is governed by kidney
damage status and estimated GFR (eGFR). Kidney damage
is typically ascertained by testing for the presence of elev-
ated albumin (albuminuria) in the urine. The model tracks
kidney damage based on two levels of albuminuria; per-
sistent microalbuminuria (sustained albumin-creatinine ra-
tio [ACR] between 30 and 299 mg/g) and macroalbumin-
uria (ACR ≥300 mg/g). We simulated kidney damage by
initially assigning the prevalence of microalbuminuria at
age 30 years and then including an annual incidence of per-
sistent microalbuminuria and an annual rate of progression
from micro- to macroalbuminuria.
Death is simulated by assigning each individual an annual
background mortality rate. CKD multipliers reflecting the
elevated mortality risk from CKD, cardiovascular disease
(CVD) mortality rates determined by myocardial infarction
(MI) and stroke events, and ESRD mortality rates were
applied per subject according to their status during simu-
lation. Risk factors and medical events are simulated an-
nually based on probability functions as described in the or-
ginal publication [15]. Model risk factors include diabetes
status, systolic blood pressure (SBP) and hypertension, left
ventricular hypertrophy (LVH), total and high-density lipo-
protein (HDL) cholesterol, and smoking status. Discrete
medical events that are modelled include stroke and coron-
ary heart disease (CHD), including MI and angina.
Individual-level risk factors and events are simulated for all
CKD stages except ESRD, which is modelled by assign-
ing mean population cost, mortality, and utility values. We
assume that patients who survive 1 year in stage 5 begin
ESRD (we do not model improvement in eGFR following
transplant) [15].




One-way sensitivity analysis, which shows the impact of a change
in key parameters of plus or minus 25%, depicted by red and blue
bars, on the cost-effectiveness ratio of annual screening versus no
screening of the full population, starting at age of 50 years.
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Screening and treatment interventions
In our simulation, confirmed micro- or macroalbuminuria
was followed by treatment with ACE inhibitors or ARBs
(fig. 1). We analysed the cost-effectiveness of different
screening rates beginning at age 50, ranging from 10-year
screening intervals to an annual screening. The different in-
tervals were applied universally to the total cohort or spe-
cifically to subgroups with varying risk factors for CKD:
subjects with diabetes, subjects with hypertension and no
diabetes, and subjects with neither diabetes nor hyperten-
sion. The impact of universal screening was also investig-
ated at various starting ages.
In order not to overestimate the benefit of microalbumin-
uria testing, the modelled screening interventions were
compared to a “no-screening” scenario (in this scenario
CKD would only be diagnosed at the advanced stage of
renal failure/ESRD) as well as to a “usual care” scenario.
The “usual care” scenario takes into account that there is
already a base level of microalbuminuria screening in daily
clinical practice. For the model, the probability for base
screening activity was taken from the US Renal Data Sys-
tem, which is 23% for subjects with diabetes and hyperten-
sion, 22% for subjects with diabetes only, 2% for subjects
with hypertension and no diabetes and 0% for subjects with
neither diabetes nor hypertension [14].
The model takes into account the published sensitivity
(73%) and specificity (96%) of microalbuminuria testing
[16]. Screening and treatment parameters of the model are
depicted in table 1 and include potential benefits resulting
from ACE inhibitor or ARB therapy after the diagnosis of
CKD. Suboptimal treatment adherence is incorporated by
the assumption that only 75% of subjects will initiate ACE
inhibitor or ARB treatment after diagnosis. The model ac-
counts for potential harm of screening as well. The prob-
ability and associated costs for both side effects secondary
to ACE inhibitor or ARB and complication due to renal
biopsy have been integrated into the model (Boulware et
al., 2006 [13] for probability of complications secondary
to ACE inhibitor and ARB; personal communication Prof.
Andreas Bock for cost of biopsy complication; personal
communication Dr. Andrea Albinger for cost of side effects
to ACE inhibitor and ARB).
In the model, subjects with confirmed micro- or macroal-
buminuria are referred to a nephrologist by the general
practitioner (GP). To assess the probability of a patient to
undergo renal biopsy after referral in Switzerland, we sent
out a questionnaire to 12 heads of nephrology departments
in University hospitals or large cantonal hospitals as well
as to one private dialysis unit (Swiss survey 2010). We re-
ceived responses from 5 centres, representing approxim-
ately 10% of all Swiss dialysis subjects, and took the aver-
age of the 5 answers as input for the model (table 1).
Population characteristics, epidemiology of CKD and
associated risk factors
To adapt the US model of Hoerger et al. [15] to the Swiss
specific situation, we modified certain demographic para-
meters. Demographic data for age 30 years was taken as
available from the demographic tables published by the
federal office of statistics for 2008 [17]. Race was also
modified as follows: Caucasian men: 50.193% (male pop-
ulation from age 20 to 39 years minus Afro-Caribbean and
Hispanic male proportion), Afro-Caribbean men: 0.005%
(Afro-Caribbean origin males without age distinction),
Hispanic men: 0.002% (South American origin males
without age distinction), Caucasian women: 49.792% (fe-
male population from age 20 to 39 years minus Afro-Carib-
bean and Hispanic female proportion), Afro-Caribbean wo-
men: 0.004% (Afro-Caribbean origin females without age
distinction), Hispanic women: 0.004% (South American
females without age distinction).
The model takes into account the annual probability of
death for each subject. The all-cause mortality rates for
men and women were taken from the Swiss Federal Office
of Statistics [18]. The calculations for the incremental mor-
tality risk in subjects with CV disease and/or CKD were
performed according to the original publication [15]. Due
to the lack of published Swiss data for ESRD mortality, we
used data from the USA [15].
The prevalence of smoking for Switzerland was taken from
the Swiss health survey 2007 for people between 25 and 64
Table 1: Screening and treatment parameter incorporated into the model.
Parameter Value° Source Swiss specific data source

















Probability of biopsy during screening:
Age <65, macroalbuminuria, no DM, no HTN
Age <65, no macroalbuminuria, no DM, no HTN














Treatment adherence 0.75 [46] no
Effect of Treatment*:
Micro- to macroalbuminuria transition
Mortality










DM: Diabetes Mellitus; HTN: Hypertension
° Value represents the relative risk/probability of an event, effect or behaviour.
* Assumed treatment with ACE inhibitor or Angiotensin II receptor blocker; relative risks are multiplied by baseline rates of patients with no treatment (e.g. baseline
probability of transition from micro- to macroalbuminuria for a patient with DM is 0.0284. Treatment with an ARB reduces this probability by 55% to 0.0128 (0.0284x0.45).
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years. The prevalence was 32.2% for men and 23.6% for
women, respectively [19].
Prevalence data of micro- and macroalbuminuria in men
and women with or without diabetes or hypertension were
extracted from the CoLaus study [20]. The CoLaus cohort
consists of 6,188 subjects aged 35 to 75 years from the
Caucasian population of Lausanne. Thus, although this
population is suitable for our analysis, it is not perfectly
representative for Switzerland. The urban CoLaus cohort
from Western Switzerland represents neither the rural re-
gions nor the Swiss German and Swiss Italian parts of the
country. To calculate the prevalence of microalbuminuria,
the same definitions as in the original paper were applied
[15]. Microalbuminuria was defined as an albumin-cre-
atinine ratio (ACR) of 30 to 299 mg/g and macroalbu-
minuria as an ACR of ≥300 mg/g, respectively. Data for
the model were gathered in a post-hoc analysis (Muri-
elle Bochud, personal communication, September 2010).
We calibrated microalbuminuria incidence and micro- to
macroalbuminuria transition rates such that the model rep-
licated the age and risk-factor specific prevalence of micro
and macroalbuminuria observed in the CoLaus study. The
baseline prevalence of persistent microalbuminuria at an
age of 30 years applied in the model was in the range of
0 to 1.9% for the different risk groups. We transformed
age category specific micro and macroalbuminuria preval-
ence rates identified in the CoLaus study into incidence
rates. We then used linear programming to identify micro to
macroalbuminuria transition rates that would most closely
match overall macroalbuminuria prevalence. Finally we
inflated the microalbuminuria incidence and macroalbu-
minuria transition rates to account for elevated mortality
in these groups as observed in the model. In certain risk
groups of the CoLaus study the prevalence of macroalbu-
minuria was lower among older patients. Possible explan-
ations for this result include uncertainty in the point es-
timates due to the small sample size, selection bias among
older age groups, and an artefact of higher mortality rates
among persons with high levels of albuminuria. Although
our model includes higher mortality due to the direct and
indirect results of macroalbuminuria, the model nonethe-
less could not replicate the level of decline observed in the
CoLaus sample, and thus might overestimates macroalbu-
minuria at older ages. However, the model’s predicted age,
race and risk-factor specific macroalbuminuria prevalence
remains well below the prevalence observed in the large
US-based NHANES sample [21].
An important risk factor of CKD is diabetes. It accelerates
CKD progression and results in higher rates of CV com-
plications and mortality. In order to adjust the model to
the Swiss-specific situation, the data input was changed.
Due to a lack of similar published Swiss data, based on
identical definitions of diabetes (sum of diagnosed diabetes
and undiagnosed diabetes, defined as fasting plasma gluc-
ose ≥7 mmol/L), the comparative prevalence data (diabetes
defined as fasting plasma glucose ≥7 mmol/L) from the
diabetes atlas of the International Diabetes Federation for
2010 were considered [22]. For the USA, the given preval-
ence rate of diabetes is 10.3% for 2010, while it is 8.9%
for Switzerland. Thus, we multiplied the prevalence and in-
cidence data in the model by 0.86 for men in order to ad-
just the values for Switzerland. To reflect the lower dia-
betes prevalence in women [24], a coefficient of 0.72 was
applied to multiply the US incidence. The baseline diabetes
prevalence at the age of 30 years applied in the model was
1.4% for men and 0.6% for women, respectively.
The original model uses systolic blood pressure values per
age and sex groups. Hypertension is assigned in the model
if systolic blood pressure is >140 mm Hg. We were not able
to identify identical Swiss data. However, since a compar-
ison of two analogous studies from the USAand Switzer-
land showed almost identical data, we used the original val-
ues from the model [23, 24]. The coefficients from the two
studies for different age groups lay between 0.99 to 1.01 for
men and 0.93 to 1.0 for women.
In our simulation, positive screening for microalbuminuria
is followed by a second physician visit to confirm its pres-
ence (fig. 1). Subjects with confirmed microalbuminuria
and diabetes received an ARB and subjects with confirmed
microalbuminuria and with or without hypertension re-
ceived an ACE inhibitor. All subjects with confirmed mi-
croalbuminuria and an estimated glomerular filtration rate
(GFR) of <60 mL/min/1.73 m2 were referred to a nephro-
logist for further diagnostic tests. Each patient with con-
firmed microalbuminuria and neither hypertension nor dia-
betes received three GP visits per year and every diagnosed
patient had an extra annual specialist visit. An additional
GP visit was not incorporated for patients with diabetes or
hypertension, since it was assumed that they were already
under routine care.
The described annual follow-up visits of patients with con-
firmed microalbuminuria are based on the daily clinical
practice of CKD management in the USA [13] and in
Switzerland (personal communication Dr. G. Keusch, Dr.
Thomas Saner, Nicole Leuzinger and Yuki Tomonaga).
Costs
The following types of costs were included in the model:
annual expected medical costs for early CKD stages and
those for stage 5 and ESRD, direct screening costs and re-
lated medical treatment costs. Screening and medical costs
were inflated to 2010 CHF using an annual inflation rate
of 3.1%. This inflation rate represents the average increase
of the health care costs for people between 25 to 35 years
from 2001 to 2009 [25].
The costs for early CKD stages in the original publication
of the model were derived from a privately insured non-
profit group model HMO (Health Maintenance Organisa-
tion), which provides comprehensive health care coverage
to 450,000 Americans in the Northwest area of the USA [6,
15, 26]. The US derived data were adjusted to the Swiss
situation where possible. The costs used for the model are
depicted in table 2. The base costs (intercept) were derived
from health care costs of people between ages 25 to 35
[25]. Since no published costs data for CKD stages 3 to 5
exist for Switzerland, we multiplied the intercept with the
corresponding coefficients from the US data.
The incremental costs for age and sex were derived from
a publication dealing with health costs risk adjustment in
Switzerland [27]. Additional costs for CKD risk factors
diabetes and hypertension were extracted from the defined
pharmaceutical cost groups (PCG) 10 and 13 [28–30] and
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deviated by only 3% from the US data [14]. Annual costs
for further complications were calculated using the coeffi-
cients from the publication by Hoerger et al. [14]
The costs for ESRD were calculated based on data obtained
by the Swiss Association for Shared Responsibilities of
Health Insurance Providers (SVK) [3]. SVK has defined a
flat fee of 497 CHF for one haemodialysis (HD) session
in a centre. We assumed that a patient has 3 sessions per
week for the whole year. The annual costs for peritoneal
dialysis (PD) are also based on a SVK flat fee and were
taken from a recent publication [31]. Costs for erythropoi-
etin treatment were added to the dialysis costs. Average
dosages for HD and PD subjects were extracted from the
SVK database [3] (Gabriela Krähemann, personal commu-
nication). The average dose per week amounted to 30.4 µg
for HD subjects and 18.5 µg for PD subjects. The average
doses were multiplied by the average price to the public
per microgram for the originator drugs Aranesp®, Eprex®,
Recormon® and Mircera®. To convert from international
units (Eprex® and Recormon®) to microgram (Aranesp®
and Mircera®), a conversion factor of 200:1 was applied.
At the time of analysis no biosimilars of erythropoietin
were prescribed to subjects in the SVK database. Annu-
al costs for ESRD with a renal transplant were taken from
Sandoz et al. and inflated for 2010 [31]. Annual costs for
HD, PD and transplantation were weighted by their preval-
ence to calculate average costs for ESRD subjects (table 2)
[3].
No data on CKD stage 5 pre-ESRD have been published
for Switzerland. We therefore applied the coefficient from
Hoerger et al. [14] between CKD stage 4 and stage pre-
ESRD.
Screening costs included an initial visit with a GP to meas-
ure microalbuminuria with an ACR test. If initial testing
was positive, a second visit was scheduled with the GP to
confirm the microalbuminuria and to estimate the GFR.
Further GP and specialist follow up visits and associated
costs for laboratory analysis, radiological and pathological
testing were also incorporated [13, 14]. Laboratory costs
were based on the List of Analysis (AL) from the Federal
Office of Public Health (Bundesamt für Gesundheit, BAG)
[32]. In July 2010, the BAG announced interims add on
fees, which were taken into consideration. In addition, the
costs for complications of renal biopsy were taken into con-
sideration.
Costs for physician visits, radiological and pathological
examinations were extracted from the Tarmed list [33].
The different relevant positions were applied according
to daily practice as communicated by Nicole Leuzinger
(MPA, practice of Dr. T. Saner) for GP related costs and by
Dr. Gérald Keusch (Nephrologist, Praxis and Dialysezen-
trum Zürich-City) for specialist related costs (table 3).
To calculate annual drug costs, we assumed that ACE in-
hibitors and ARBs were prescribed in the largest available
pack. The approved prices to the public were extracted
from the official List of Specialities (SL) in summer 2010
[34]. It was assumed that the medications were dispensed
quarterly through pharmacies. The cost stabilisation contri-
bution of 2.5%, as well as the service based remuneration
to pharmacists (Leistungsorientierte Abgeltung, LOA) ac-
cording to the declaration of the BAG effective since 2007
[35] were considered. For both ACE inhibitors and ARBs,
the prices for originator drugs as well as corresponding
generics were included in the analysis, given that the drugs
had a renal indication in their summary of product char-
acteristics [36]. Annual drug costs were calculated for the
dosage used in the registration study and/or recommended
in the respective summary of product characteristics (table
3). To estimate average costs per drug group, the different
drug prices were weighted by their sales market share
between July 2009 and July 2010 according to Swiss IMS
data [37]. For example, while the approved prices of 9
available Losartan generics were very similar, their market
share varied from 0.05% to 7.2%. Thus, the price of the
generic Losartan market share leader, Losartan Mepha, was
weighted with the cumulative market share for the group of
Losartan generics.
Quality-Adjusted-Life-Years
Quality-Adjusted-Life-Years (QALYs) were calculated as
the present value of future life-years, taking into considera-
tion the utility values for the different GFR levels as well as
for CKD related complications such as myocardial infarc-
tion (MI), non-MI coronary heart disease and stroke [14].
Outcomes and statistics
Incremental cost-effectiveness ratios
The primary outcome was the incremental cost-effective-
ness ratio, expressed in the additional lifetime costs result-
ing from an intervention divided by the impact on QALYs.
Lifetime costs and QALYs were simulated for 1 million in-
dividuals for the different screening scenarios. Simulation
of subjects started from the age of 30 years, but costs and
QALYs were only calculated from 50 years onwards.
An annual discount rate of 3% was applied for both costs
and QALYs.
Sensitivity analysis
We conducted a 1-way sensitivity analysis to evaluate the
impact of various key parameters on the cost-effectiveness
results. Figure 2 shows the range of ICERs for annual
screening compared to routine screening in the overall pop-
ulation while changing key parameters + and – 25%. The
following parameters were investigated:
1. CKD risk and progression factors: diabetes incidence,
microalbuminuria incidence and progression to macroalbu-
minuria.
2. Screening costs.
3. Annual discount rate: the annual discount rate varied
from 0%–5%
We also conducted a limited probabilistic sensitivity ana-
lysis (PSA) by introducing second-order variability in ma-
jor parameters, including all medical costs, microalbumin-
uria incidence and progression to macroalbuminuria. In the
PSA, we varied parameter groups simultaneously using
independent multiplier values based on normal distribu-
tions for event costs and lognormal distributions for annual
costs. Distributions were imputed such that the 95% con-
fidence interval (CI) for each value ranged + or – 20%
[38]. We also varied the incidence of microalbuminuria and
the transition rate to macroalbuminuria. As these values
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were calibrated using the model, we did not have relevant
sample size statistics necessary for estimating a beta dis-
tribution and therefore varied these parameters based on a
normal distribution with a 95% CI with a range of + or –
20%. We ran the model as a 2-dimentional simulation with
inner loop populations of 10,000 replicated 10,000 times
and cost-effectiveness acceptability curves (CEACs) based
on the PSA were derived. CEACs depict the probability
that each scenario is the most cost-effective at any partic-
ular willingness to pay (WTP) per QALY gained based on
the expected net monetary benefits, which is calculated as
ΔQALY * WTP – Δcost [39].
Results
Costs and incremental cost-effectiveness ratios (ICER)
were calculated for each screening intervention and com-
pared to no screening, compared to the usual care scenario,
and compared to the next less costly intervention (table 4).
Table 2: General medical cost equation.
Cost item Cost (CHF/patient/year)* Source Swiss specific data source°
Intercept +2,418 [25] yes
Demographic influence
Age (per increasing year) +82 [27] yes
Gender (male) -246 [27] yes
Influence of chronic kidney disease stage 2-4
GFR 15-29 +15,719 [14, 26] no
GFR 30-59 +8,464 [14, 26] no
GFR 60-89 +6,288 [14, 26] no
Influence of morbidities/behaviour
Proteinuria +7,013 [14, 26] no
DM +2,931 [28] yes
HTN +1,856 [28] yes
Smoking +725 [14, 26] yes
Influence of chronic kidney disease x morbidities
DM X GFR 15-29 +5,804 [14, 26] no
HTN X GFR 60-89 -1,935 [14, 26] no
HTN X GFR 30-59 -2,902 [14, 26] no
HTN X GFR 15-29 -4,353 [14, 26] no
Influence of chronic kidney disease stage 5
Pre ESRD +31,079 [14, 26] no
ESRD +78,049 [3, 31, 32] yes
GFR: Glomerular filtration rate in ml/min; DM: Diabetes Mellitus; HTN: Hypertension; ESRD: End stage renal disease
* In the model, for each subject costs were added to or subtracted from the intercept according to the corresponding sex, age and morbidities.
° For parameters, where no Swiss specific data source exists, we multiplied the Swiss specific intercept with the corresponding coefficients from the US data.
Table 3: Medical intervention costs.
Cost item Cost per item (CHF) Source Swiss specific data source
Screening by generalist
Initial visit 44.14 yes
Second visit if positive during first visit 53.50
[13, 14, 33], Nicole Leuzinger, personal
communication (July 2010) yes
Diagnosis visit by specialist if GFR <60
DM or HTN# 886.26 [13, 14], Gérald Keusch, personal
communication (July 2010)
yes
Neither DM nor HTN but
Macroalbuminuria and age <65* 2,587.99 yes
Microalbuminuria and age <65° 1,737.12 yes
Age ≥65§ 1,311.69
[13, 14], Gérald Keusch, personal
communication (July 2010)
yes
Annual specialist follow-up if GFR <60
All diagnosed patients 389.03 [13, 14], Gérald Keusch, personal
communication (July 2010)
yes
3 annual generalist visits for diagnosed patients with





Diagnosed patients with no DM 244.92
[32, 36, 37]
yes
DM: Diabetes Mellitus; GFR: Glomerular filtration rate in ml/min; HTN: Hypertension
# Diagnostic tests + 10% chance of kidney biopsy *Diagnostic tests + 90% chance of kidney biopsy; ° Diagnostic tests + 50% chance of kidney biopsy; § Diagnostic tests +
30% chance of kidney biopsy
Example of a diagnosed patient with macroalbuminuria at age <65 years with neither HTN nor DM: CHF44.14 for initial screening visit + CHF53.50 for second screening
visit + CHF2,587.99 for diagnosis visit by specialist = CHF2,685.63 total costs for screening and diagnosis.
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Costs were rounded to the nearest 100 CHF and cost-effect-
iveness ratios to the nearest 1,000 CHF/QALY.
All screening scenarios increased both costs and QALYs
for the total population. An annual screening has an ICER
of 83,000 CHF/QALY relative to usual care and 66,000
CHF/QALY compared to no screening. Prolonging the
screening interval decreases the ICER. A 10-year interval
brings down the ICER to below 30,000 CHF/QALY relat-
ive to both no screening and usual-care. This screening fre-
quency reduces the cumulative lifetime incidence of ESRD
by 5%, from 0.0365 to 0.0348, compared to no screening.
A 5% decrease in ESRD patients would represent a reduc-
tion of 184 ESRD subjects and associated annual costs of
14.35 million CHF.
The ICERs for screening of CKD high risk groups are also
listed in table 4. For subjects with diabetes all screening
scenarios have an ICER below 50,000 CHF/QALY and
below 30,000 CHF/QALY compared to usual care and no
screening, respectively. Due to the high expected rate of
screening in usual care, a 10-year screening interval res-
ults in lower costs than usual care while achieving slightly
higher QALYs.
For subjects with hypertension (no current diabetes at age
50) screening at all tested frequencies leads to an ICER of
below 50,000 CHF/QALY compared to no or usual rates of
Figure 3
Cost-effectiveness Acceptability Curves.
U10: screening at 10-year interval, u5: screening at 5-year interval;
u2: screening at 2-year interval: u1 annual screening; Noscrn: No
screening scenario; Routine: usual care scenario
Cost-effectiveness acceptability curves show the probability of each
scenario having the highest net monetary benefits (y-axis) based
on willingness to pay from 0 CHF to 200,000 CHF (x-axis).
screening. Screening intervals ≥5-years further reduce the
ICER to ≤19,000 CHF/QALY relative to both usual care
and no screening. In contrast to the CKD high risk groups,
screening of subjects with neither diabetes nor hyperten-
sion is not cost-effective unless performed at an interval of
at least 2 years.
Costs for the initial microalbuminuria screening visit
amount to 44.14 CHF (table 3), comprising of the costs for
the physician visit and the ACR testing. If the quantitative
microalbuminuria test could be integrated into an ordinary
scheduled check-up visit, the screening costs could be re-
duced to the pure ACR testing cost of 15.00 CHF. Such an
approach would further improve the cost-effectiveness and
bring down the ICER for an annual screening of the total
population beginning at age 50 years from 66,000 CHF/
QALY to 32,000 CHF/QALY.
The costs associated with one year of ESRD at 78,049 CHF
would cover 5,203 ACR tests provided during pre-sched-
uled practice visits, which would allow for >150 newly
identified subjects with persistent microalbuminuria when
screening the total population at an age of 50 years [20].
Sensitivity analyses
Figure 2 depicts the results of a 1-way sensitivity analysis.
The ICER of the base case is 66,000 CHF/QALY and
no parameter modifications result in a change of >23%
or an increase of the cost-effectiveness ratio to >79,000
CHF. Modifications in only 3 parameters led to a change
of ≥20% in the cost-effectiveness ratios: microalbuminuria
incidence (+20% when increasing incidence by 25%), dis-
count rate (–23% when setting rate at 0% and +20% when
setting it at 5%). Results were least sensitive to changes in
diabetes incidence and micro- to macroalbuminuria trans-
ition rate.
Figure 3 shows CEACs based on the outputs of the PSA.
In the overall population, screening at 10-year intervals
is most likely to have the highest net marginal benefits
from a WTP per QALY gained of 20,000 CHF to about
90,000 CHF, when it is overtaken by 5-year screening.
Among the population with diabetes incidence at age 50,
the 5-year screening interval has the highest probability of
being most cost-effective from a WTP of 15,000 CHF to
60,000 CHF, when 2-year interval screening is more cost-
effective. In the population with hypertension, the 5-year
screening interval is probably most cost-effective from a
WTP of 17,500 CHF to 140,000 CHF. For the population
with no current hypertension nor diabetes, the 10-year
screening interval scenario becomes cost effective at WTP
greater than 25,000 CHF. For the total population as well
as for the different subgroups the probability of the most
cost-effective screening interval remained below 65% at
the proposed ICER threshold of 71,000 CHF.
Discussion
In this study we demonstrated that microalbuminuria
screening starting at an age of 50 years is cost-effective for
subjects with diabetes or hypertension with intervals of 2
or 5 years, respectively. In contrast to the situation in CKD
high risk groups, screening of the total population or sub-
jects with neither diabetes nor hypertension can only be
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considered cost-effective when conducted at 10-year inter-
vals.
Various definitions of the threshold for judging the cost-
effectiveness of an intervention exist. While the National
Institute for Health and Clinical Excellence (NICE) in the
UK proposes a band width of £20,000/QALY to £30,000/
QALY, the World Health Organization (WHO) considers a
value below the annual per capita gross domestic product
(GDP), which amounted to 71,000 CHF in 2008 in
Switzerland, as very cost-effective [40]. Another reference
value often used in the literature is $50,000/QALY [41]. In
order to judge the cost-effectiveness of our results we relate
to the WHO recommendation.
The cost-effectiveness ratios for annual screening of sub-
jects with diabetes or hypertension are below 50,000 CHF/
QALY and thus appear cost-effective according to the vari-
ous thresholds proposed. However, the cost-effective
screening frequency has to be determined by looking at the
ICERs comparing a lower versus a higher screening fre-
quency. The screening of the DM population is cost-ef-
fective at a 2-year frequency, as the ICER of 54,000 CHF
is below the threshold of 71,000 CHF, while it is above
the threshold at an annual frequency (ICER of 241,000 vs.
2-year frequency). This result is confirmed by the PSA as
the 2-year screening has the highest probability of being the
most cost-effective intervention starting from a threshold
of around 50,000 CHF. The screening of the HTN popula-
tion is cost-effective at a 5-year frequency (ICER of 33,000
vs. 10-year frequency) but not at a 2-year frequency as the
ICER of 163,000 CHF is above the threshold. This result is
confirmed by the PSA, where the 2-year frequency domin-
ates the 5-year frequency from a threshold of around CHF
150,000. The screening of the non DM or HTN population
is cost-effective at a 10-year frequency with an ICER of
34,000 versus usual care.
Since screening for micro-albuminuria will identify sub-
jects at a very early disease stage, prolonging the screening
interval will not have a major negative impact on the cu-
mulative lifetime ESRD incidence.
Integrating quantitative ACR testing into pre-scheduled
routine checkups would reduce initial screening costs and
further improve the cost-effectiveness of the screening in-
tervention in all patient groups. Hoerger et al. [14] demon-
strated that initiating screening at the age of 50 years
provides the optimal cost-effectiveness for subjects with
diabetes and hypertension in the US setting. However, for
the total population a starting age of 60 years would lead to
an improved cost-effectiveness ratio.
Recent reports have shown that, as in many other countries,
there is a high level of unrecognised renal disease in
Switzerland. The investigators of the Swiss SALPADIA
study found, in a large, healthy, general population (n =
6,317), a prevalence of CKD stages 3–5 (defined as eGFR
<60 mL/min/1.73 m2) of 13% for men and 36% for women,
at an age of ≥65 years [24]. In a large population based co-
hort (n = 6,188) of subjects aged 35 to 75 years from the
Table 4: Cost-effectiveness results, from 50 years onwards.
Incremental Cost-Effectiveness Ratio (CHF/QALYs)Lifetime Costs
(CHF)
QALYs
vs. no screening vs. usual care vs. next less costly
ESRD Incidence
Total population
No Screening 247,000 17.515 0.036
Usual Care 247,468 17.520 29,000 0.036
10-year screening 247,682 17.529 27,000 26,000 0.035
5-year screening 247,792 17.530 32,000 33,000 68,000 0.035
2-year screening 248,021 17.531 44,000 51,000 231,000 0.034
Annual screening 248,392 17.531 66,000 83,000 1,295,000 0.034
DM population
No Screening 297,200 16.173 0.145
10-year screening 297,800 16.202 18,000 0.140
Usual Care 297,870 16.202 22,000 0.140
5-year screening 297,890 16.208 18,000 3,000 0.139
2-year screening 298,100 16.211 22,000 22,000 54,000 0.139
Annual screening 298,400 16.213 29,000 49,000 241,000 0.138
HTN population
No Screening 252,400 16.888 0.054
Usual Care 252,600 16.895 27,000 0.052
10-year screening 252,700 16.906 18,000 11,000 0.051
5-year screening 252,800 16.909 19,000 15,000 33,000 0.051
2-year screening 253,000 16.910 26,000 25,000 163,000 0.050
Annual screening 253,300 16.910 40,000 47,000 1,339,000 0.050
No current DM or HTN
No Screening 247,200 18.201 0.017
Usual Care 247,300 18.203 31,000 0.017
10-year screening 247,600 18.212 34,000 34,000 0.016
5-year screening 247,700 18.213 41,000 43,000 155,000 0.016
2-year screening 248,000 18.213 58,000 64,000 380,000 0.016
Annual screening 248,400 18.213 88,000 100,000 2,064,000 0.016
QALYs: Quality-Adjusted-Life-Years; ESRD: End-stage renal disease; DM: Diabetes Mellitus; HTN: Hypertension
The scenarios are ranked according to increasing costs for each population.
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city of Lausanne (the CoLaus cohort) that the prevalence of
microalbuminuria was 6.3% [20]. Finally, in the frame of
a pharmacy based screening activity, 22% of 800 voluntar-
ily tested individuals had detectable microalbuminuria. Ac-
cording to an applied renal risk score, comprising of ACR
level, familial and personal anamnesis and blood pressure,
75% of all screening participants had a moderate to high
CKD risk and were referred to their GP for further test-
ing [42]. Hence, there is a high prevalence of subjects with
putative early stages of CKD in Switzerland, who could
potentially benefit from a CKD screening programme and
subsequent treatment interventions.
A further US study assessed macroalbuminuria screening
using a dipstick test during a GP visit followed by ACE
inhibitor or ARBs treatment for the general population
or subjects with hypertension [13]. The initial screening
costs amounted to $44.15 and were significantly lower than
in the simulation of Hoerger et al. [14]. However, since
the prevalence of macroalbuminuria is several times lower
than the one for microalbuminuria, CKD subjects are only
identified later in the disease progression and at higher
costs, and have thus a reduced opportunity to benefit from
medical interventions. Nevertheless, the results of Boul-
ware et al. [13] support annual screening of subjects with
hypertension, even starting at an age of 30 years, from a
societal perspective. Screening of the general population
only becomes favourable at longer screening intervals and/
or when starting at an age of ≥50 years.
Based on data of the large PREVEND cohort (n = 8,592) of
people aged 28 to 75 years, Dutch investigators described a
total population-based, one-time microalbuminuria screen-
ing as being cost-effective over a period of 8 years with an
estimated € 22,000 per life year gained [12]. In the frame
of the PREVEND study, a cheap microalbuminuria pre-
screening was done. Participants were invited to send a vi-
al with their first morning void of urine to a central labor-
atory by mail. This approach allowed the initial screening
costs to be limited to € 7, which is much lower than in the
previously discussed studies. Another important difference
in the Dutch study is the fact that they included hospital-
isations for various CV events in the model costs. Adding
these costs improves the cost-effectiveness of early CKD
detection and subsequent medical intervention with ACE
inhibitors. A clear strength of the model of Boersma et al.
[12] is the integration of epidemiological and efficacy data
out of a large population-based observational cohort.
The microsimulation model applied for this study has sev-
eral strengths and limitations, which have previously been
described [14, 15]. The most important strengths are the
comprehensiveness of the model including all stages of
CKD, risk factors, complications, treatment adherence and
possible harm of interventions. The most important limita-
tions are the extrapolation of data from shorter studies for
long term modelling, not considering costs for CV com-
plications and restricting costs to medical interventions.
The study of Boulware et al. [13] demonstrated that indir-
ect costs due to lost wages for nonworking subjects were an
important contributor to the cost-effectiveness when ana-
lysing the situation from a societal perspective.
Our cost-effectiveness analysis for Switzerland has several
limitations as well. Since we have not been able to gather
identical Swiss specific information for all epidemiological
data and medical intervention costs, we were in some cases
obligated to run the model with data and assumptions from
the USA. While it was possible to identify local epidemi-
ological data for micro- and macroalbuminuria, we had to
refer to the information from the International Federation
of Diabetes to get comparable data for the diabetes inciden-
ce and prevalence. However, comparing other sources for
diabetes prevalence in the USA and Switzerland points to a
slightly lower coefficient than the one applied in this study
[19, 23, 24]. This could have led to a slight overestimation
of the cost-effectiveness. On the contrary, the ICER is not
very sensitive to the diabetes incidence as shown in figure
2.
With regard to the rate of microalbuminuria screening in
the usual care scenario, we applied the same values for sub-
jects with diabetes (20%), subjects with hypertension (2%)
and subjects with both diabetes and hypertension (23%) as
used for the US modelling. Yet the medical practice might
differ in Switzerland. A recent study showed that among
Swiss and German subjects with hypertension referred to a
cardiologist, 53.1% had a detectable macroalbuminuria on
dipstick testing that had only been pre-diagnosed in 8.95%
of cases [43]. In subjects with diabetes, a microalbuminuria
screening rate of 15.5% was described in 2001 for Switzer-
land [44]. If the current medical practice in our country
would still show a lower base screening activity compared
to the implemented model parameters, the cost-effective-
ness would be further improved compared to the reported
results relative to usual care.
Due to the fact that we had no direct access to individual
patient data for both clinical parameters and for costs of
medical interventions, we had to extrapolate costs for the
different early CKD stages using the coefficients from the
US. Nevertheless, this should not have had an important
impact on our results, given that the probability analysis
showed that the real values may not be much different, and
the cost-effectiveness results were not very sensitive to pre-
ESRD CKD stage costs [14].
Screening programmes and secondary prevention activities
often meet the resistance of health policy makers and au-
thorities. While political pressure puts the focus of politi-
cians on short term results and visibility, the public health
and costs benefits of targeted screening programmes will
only become evident in the long term. Our recommenda-
tion to screen subjects with diabetes for microalbuminuria
is supported by a former Swiss study, which found that a
multi-factorial intervention approach could be both cost-
and life-saving [44].
In conclusion, our results suggest that microalbuminuria
screening and subsequent treatment of subjects with dia-
betes or hypertension may be cost-effective, depending on
the applied screening interval. For the general population
screening only becomes clearly cost-effective, when using
a prolonged interval of 10-years. Future health economic
modelling might benefit as more detailed Swiss specific
data become available, from choosing a low fee approach
for initial screening and from including costs for CV com-
plications and indirect costs due to lost wages and op-
portunistic expenses. Our results may provide health care
policy makers with helpful information for considering the
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implementation of local CKD screening and treatment
guidelines.
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Figures (large format)
Figure 1
Scheme of screening and treatment interventions.
ACE/ARB: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers; ACR: Urine albumin-creatinine ratio; GFR: Glomerular
filtration rate.
The same screening and treatment scheme does apply for patients with macroalbuminuria. Such patients will also be detected in a
microalbuminuria screening.
Modified and reproduced from Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, et al.Am J Kidney Dis. 2010:55(3):463–73,
with the permission of Elsevier.
Figure 2
Sensitivity Analysis.
One-way sensitivity analysis, which shows the impact of a change in key parameters of plus or minus 25%, depicted by red and blue bars, on
the cost-effectiveness ratio of annual screening versus no screening of the full population, starting at age of 50 years.
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Figure 3
Cost-effectiveness Acceptability Curves.
U10: screening at 10-year interval, u5: screening at 5-year interval; u2: screening at 2-year interval: u1 annual screening; Noscrn: No screening
scenario; Routine: usual care scenario
Cost-effectiveness acceptability curves show the probability of each scenario having the highest net monetary benefits (y-axis) based on
willingness to pay from 0 CHF to 200,000 CHF (x-axis).
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